Intuitive Surgical (NASDAQ: ISRG) reported Q1 EPS of $2.61, $0.09 worse than the analyst estimate of $2.70. Revenue for the quarter came in at $973.7 million versus the consensus estimate of $973.43 million.

• Worldwide da Vinci procedures grew approximately 18% compared with the first quarter of 2018, driven primarily by growth in U.S. general surgery procedures and worldwide urologic procedures.
• The Company shipped 235 da Vinci Surgical Systems, an increase of 27% compared with 185 in the first quarter of 2018.
• The Company grew its installed base to 5,114 systems as of March 31, 2019, an increase of 13% compared with 4,528 as of the end of the first quarter of 2018.
• First quarter 2019 revenue of $974 million grew approximately 15% compared with $848 million for the first quarter of 2018.
• First quarter 2019 GAAP net income was $307 million, or $2.56 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018.
• First quarter 2019 non-GAAP* net income was $312 million, or $2.61 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018.
• In February 2019, the Company received U.S. Food and Drug Administration (“FDA”) clearance for the IonTM endoluminal system, the Company’s new flexible robotic-assisted catheter-based platform, designed to navigate through very small lung airways to reach peripheral nodules for biopsies.
• In February 2019, the Company received FDA clearance for the IRISTM augmented reality product, designed to aid surgeons in both pre- and intra-operative settings by delivering a 3D image of the patient anatomy.
• In March 2019, the Company received FDA clearance for the da Vinci SP® Surgical System for use in certain transoral otolaryngology procedures in adults.

For earnings history and earnings-related data on Intuitive Surgical (ISRG) click here.